Chapter 46 – Obesity in Hypertension: Role of Diet and Drugs

[1]  A. Rocchini.  Obesity and Blood Pressure Regulation , 2003 .

[2]  G. Bakris,et al.  Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension , 2002, Journal of hypertension.

[3]  Megan Jehn,et al.  Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). , 2002, Hypertension.

[4]  Arya M. Sharma,et al.  Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension , 2002, Journal of hypertension.

[5]  N. Cutler,et al.  Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial , 2002, Journal of Human Hypertension.

[6]  K. Fujioka,et al.  Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors , 2002, Journal of Human Hypertension.

[7]  J. Ard,et al.  DASH (Dietary Approaches to Stop Hypertension) Diet Is Effective Treatment for Stage 1 Isolated Systolic Hypertension , 2001, Hypertension.

[8]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[9]  N. Milas,et al.  Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II , 2001, Annals of Internal Medicine.

[10]  S. Toubro,et al.  Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial , 2001, International Journal of Obesity.

[11]  L. Appel,et al.  The effect of dietary patterns on blood pressure control in hypertensive patients: results from the Dietary Approaches to Stop Hypertension (DASH) trial. , 2000, American journal of hypertension.

[12]  A. Heck,et al.  Orlistat, a New Lipase Inhibitor for the Management of Obesity , 2000, Pharmacotherapy.

[13]  G A Colditz,et al.  Lifetime health and economic consequences of obesity. , 1999, Archives of internal medicine.

[14]  P. Conlin,et al.  The dietary approaches to stop hypertension (DASH) clinical trial: implications for lifestyle modifications in the treatment of hypertensive patients. , 1999, Cardiology in review.

[15]  L. Appel,et al.  Effect of dietary patterns on ambulatory blood pressure : results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. , 1999, Hypertension.

[16]  Adesh K. Jain,et al.  Sibutramine produces dose-related weight loss. , 1999, Obesity research.

[17]  P. Vague,et al.  Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. , 1999, The American journal of medicine.

[18]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.

[19]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[20]  P. Whelton,et al.  Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.

[21]  Claude Bouchard,et al.  Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary , 1998 .

[22]  K. Flegal,et al.  Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994). , 1997, Obesity research.

[23]  G. Bray,et al.  A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. , 1997, The New England journal of medicine.

[24]  F. Pi‐Sunyer.  A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. , 1996, Clinical therapeutics.

[25]  R N Pierson,et al.  How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? , 1996, American journal of epidemiology.

[26]  J. Hall,et al.  Louis K. Dahl Memorial Lecture. Renal and cardiovascular mechanisms of hypertension in obesity. , 1994, Hypertension.

[27]  T. Wadden,et al.  One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. , 1994, Journal of consulting and clinical psychology.

[28]  C. Lewis,et al.  Treatment of Mild Hypertension Study: Final Results , 1993 .

[29]  N. Cook,et al.  Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. , 1993, Archives of internal medicine.

[30]  F. Pi‐Sunyer,et al.  Medical Hazards of Obesity , 1993, Annals of Internal Medicine.

[31]  T. Wadden,et al.  Behavioral assessment and treatment of markedly obese patients. , 1992 .

[32]  M. Blaufox,et al.  The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. , 1992, Archives of internal medicine.

[33]  F. Pi‐Sunyer,et al.  Health implications of obesity. , 1991, The American journal of clinical nutrition.

[34]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[35]  S. Corrigan,et al.  Weight Reduction in the Prevention and Treatment of Hypertension: A Review of Representative Clinical Trials , 1991, American journal of health promotion : AJHP.

[36]  P. Lavin,et al.  Weight loss outcome and health benefits associated with the Optifast program in the treatment of obesity. , 1989, International journal of obesity.

[37]  J. Cutler,et al.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. , 1988, Archives of internal medicine.

[38]  A. Dyer,et al.  Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program. , 1987, JAMA.

[39]  H. Halkin,et al.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. , 1985, The Journal of clinical investigation.

[40]  M. Blaufox,et al.  Dietary therapy slows the return of hypertension after stopping prolonged medication. , 1985, JAMA.

[41]  Manning Feinleib,et al.  Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.

[42]  M. M. Jones,et al.  Cardiovascular changes after weight reduction in obesity hypertension. , 1983, Annals of internal medicine.

[43]  M. Modan,et al.  Body weight reduction necessary to attain normotension in the overweight hypertensive patient. , 1981, International journal of obesity.